Clinical Trials
9 trialsNCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03581500 2025-04-23
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05807126 2024-05-02
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05034562 2024-03-07
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04483414 2023-05-19
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT00963300 2018-11-26
MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
University of Texas Southwestern Medical Center
Phase NA Withdrawn
NCT02169063 2016-08-31
Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer
University of Washington
Phase NA Withdrawn
NCT00796874 2013-07-25
Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance
Roswell Park Cancer Institute
Phase NA Withdrawn